Unichem Laboratories Ltd
About
Unichem Laboratories was founded by Amrut Mody with an objective of delivering better health through its products. These products span therapeutic areas like gastroenterology, diabetology, cardiology, neurology, psychiatry, anti-bacterials, pain management, and anti-infectives. The company has 6 manufacturing facilities located in Goa, Ghaziabad, Pithampur, Baddi, Roha, and Kolhapur, most of which are accredited by international organisations like the Food and Drug Administration (FDA) of the US and the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK. Its primary businesses are formulations, active pharmaceutical ingredients (APIs), and contract manufacturing. Its R&D activities also focus on the development of cost-effective biosimilars, APIs, and intermediates, recombinant technology for peptides, proteins, and enzymes, among others.
Featured In Fortune India Ranking
Financial Data 2024
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 1884 38.1% | 1364 0.4% | 1359 -1.1% | 1373 11.5% | 1232 -6.2% | 1313 -63.4% | 3583 304.4% | 886 -35.3% | 1370 10.9% | 1236 -1.1% | 1249 15.8% | 1079 21.0% | 892 4.0% | 857 13.7% | 754 -0.7% | 760 - |
| Net Operating Income (INR Cr) | 1705 26.94% | 1343 5.76% | 1270 2.81% | 1235 11.91% | 1104 -6.47% | 1180 44.86% | 815 16.75% | 698 -47.64% | 1333 10.89% | 1202 6.03% | 1133 4.87% | 1081 23.46% | 875 6.24% | 824 10.76% | 744 1.71% | 731 9.84% |
| Profit (INR Cr) | -70 - | -202 - | 33 -3.7% | 34 - | -60 - | -24 - | 2545 2241.7% | 109 0.5% | 108 43.4% | 75 -55.5% | 169 49.5% | 113 58.9% | 71 -25.0% | 95 -22.9% | 123 14.0% | 108 - |
| Assets (INR Cr) | 2647 -5.2% | 2792 -7.3% | 3012 11.1% | 2711 -2.0% | 2766 -2.6% | 2839 -0.3% | 2846 135.8% | 1207 18.1% | 1022 11.2% | 919 5.2% | 874 10.8% | 789 6.5% | 740 9.4% | 676 13.0% | 599 14.2% | 524 - |
| Net Worth (INR Cr) | 2362 -3.0% | 2435 -7.0% | 2618 2.4% | 2557 1.0% | 2531 -3.4% | 2620 -2.3% | 2680 152.0% | 1064 11.5% | 954 10.0% | 868 6.2% | 817 12.3% | 727 10.1% | 661 6.9% | 618 9.7% | 563 16.2% | 484 17.7% |
| Employee Cost (INR Cr) | 393 10.3% | 356 7.8% | 330 7.7% | 307 12.3% | 273 14.6% | 239 18.9% | 201 18.7% | 169 -34.0% | 256 14.7% | 223 19.1% | 187 13.6% | 165 17.7% | 140 13.0% | 124 20.2% | 103 2.1% | 101 - |
| Interest Cost (INR Cr) | 23 | 17 | 6 | 5 | 8 | 8 | 8 | 3 | 3 | 3 | 3 | 3 | 4 | 2 | 2 | 3 |
| Cash & Bank Balance (INR Cr) | 154 | 185 | 114 | 82 | 234 | 201 | 681 | 16 | 20 | 27 | 52 | 25 | 23 | 15 | 24 | 34 |
| Total Debt (INR Cr) | 248 | 314 | 349 | 119 | 207 | 200 | 151 | 98 | 36 | 22 | 26 | 27 | 46 | 51 | 36 | 40 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | - | - | 2.4% | 2.5% | - | - | 71.0% | 12.3% | 7.9% | 6.1% | 13.6% | 10.5% | 8.0% | 11.1% | 16.3% | 14.2% |
| Profit As % Of Assets | - | - | 1.1% | 1.3% | - | - | 89.4% | 9.0% | 10.6% | 8.2% | 19.4% | 14.4% | 9.6% | 14.0% | 20.6% | 20.6% |
| Profit As % Of Networth | - | - | 1.3% | 1.3% | - | - | 95.0% | 10.2% | 11.3% | 8.7% | 20.7% | 15.6% | 10.8% | 15.4% | 21.9% | 22.3% |
| Interest Cost to EBITDA % | - | - | 8.5% | 5.6% | - | - | - | - | 1.8% | 3.0% | 1.8% | 1.9% | 3.5% | 1.6% | 1.4% | 1.8% |
| Debt to Equity Ratio | 0.10 | 0.13 | 0.13 | 0.05 | 0.08 | 0.08 | 0.06 | 0.09 | 0.04 | 0.03 | 0.03 | 0.04 | 0.07 | 0.08 | 0.06 | 0.08 |
| RONW | - | - | 1.2% | 1.1% | - | - | 136.0% | 10.8% | 11.9% | 8.9% | 14.6% | 16.3% | 11.2% | 16.1% | 23.5% | 24.1% |
| ROCE | 0.4% | -4.5% | 0.9% | 1.7% | -2.4% | -2.4% | 126.1% | 9.0% | 14.5% | 9.0% | 18.6% | 19.5% | 13.9% | 20.2% | 27.7% | 27.1% |